Posted 3rd February 2020 by Liv Sewell
Automation and digitisation are becoming increasingly important in the modern environment of bioprocesses 4.0. A new wave of biopharmaceutical manufacturing is already breaking. Driven by the PAT initiative and the goal of a well-understood and optimally controlled process, the digital transformation of bioprocesses is inevitable.
Posted 17th January 2020 by Joshua Sewell
Despite recent advances in the gene therapy field, significant challenges lie ahead for the consistent manufacturing and release of these medicines. Analytical methods and automation need to keep pace as more medicines move towards the market and more quality control resources are required. Well-developed methods on robust platforms will be crucial to ensure the quality of these novel medicines for the doctors and patients who need them.
Posted 16th December 2019 by Liv Sewell
Ahead of the 3rd Global Bioprocessing, Bioanalytics and ATMP Manufacturing Congress in Dublin, we consider how Ireland is uniquely positioned to play a significant role in the next generation of biopharmaceutical manufacturing and delivery of life changing medicines.
Posted 19th July 2017 by Jane Williams
Although the messenger RNA (mRNA) and its roles in the cell were discovered more than half a century ago, it took more than four decades to consider its uses as biologics for human therapeutics. Nowadays, synthetic mRNA, produced in vitro by various enzymatic and non-enzymatic processes, is broadly used in vaccination, immunotherapeutics and even transient gene compensation.